Kratom Consumer Advisory Council (KCAC) Releases White Paper Debunking Claims on Safety of '7' Products
Kratom Consumer Advisory Council (KCAC) today released a comprehensive white paper challenging recent claims that products containing isolated 7-hydroxymitragynine (also known as '7') are safe for widespread, uncontrolled consumer use. The white paper, " Have '7' Products with 7-Hydroxymitragynine (7-OH) Been Proven to Be Safe? " directly refutes assertions made in a July 7 press release by the Holistic Alternative Recovery Trust (HART), which KCAC says misrepresented findings from a report HART itself commissioned from healthcare consulting firm Marwood Group.
KCAC Chair Dr. C. Michael White, Pharm.D., FCP, FCCP, FASHP, and Distinguished Professor of Pharmacy Practice at the University of Connecticut, issued a stark warning:
'It is dangerously misleading to suggest that 7 products are safe for public sale without medical oversight. Marwood Group's own report, despite being commissioned by HART, clearly concludes that synthetic 7-hydroxymitragynine is a potent opioid agonist with high abuse potential, rapid tolerance development, and physical dependence in animal models. HART's attempt to erase key parts of the report after publication, including these risk statements, is an alarming act of public deception that endangers consumers.'
The KCAC white paper cites the following key concerns from the Marwood Group report that HART initially published and then quietly removed:
The KCAC paper refutes Marwood Group's assertion that 7-hydroxymitragynine has a lower risk of respiratory depression. They used a surrogate marker called beta-arrestin recruitment to say the risk was lower without looking at actual animal studies where breathing was assessed and shown to be depressed, just like with morphine. It also provides a balanced perspective on anecdotal experiences with 7 products where consumers report widespread recreational use for euphoria and suffering from severe addiction.
'We've seen this playbook before, downplaying the risks of potent opioids while encouraging unregulated use. The opioid crisis of the 2000s began with similar false assurances,' said Dr. White. 'We must not repeat history with synthetic 7-hydroxymitragynine. These products must be evaluated through rigorous clinical trials and carefully controlled, not sold like candy at gas stations.'
The white paper also highlights KCAC's support for the FDA's July 15 warning letters against firms illegally marketing synthetic 7-hydroxymitragynine products and making unsubstantiated medical claims.
KCAC calls on regulators, lawmakers, and the media to take a clear-eyed view of the risks posed by synthetic 7-hydroxymitragynine products and urges a halt to the sale of these potent synthetic derivatives outside of clinical or research settings.
The full white paper, 'Have '7' Products with 7-Hydroxymitragynine (7-OH) Been Proven to Be Safe?' is available here.
About Kratom Consumer Advisory Council (KCAC)
Kratom Consumer Advisory Council (KCAC) is an independent board made up of a clinician-scientist and consumers that uses the strongest available evidence to produce position statements that promote evidence-based policy. The KCAC is supported by the Global Kratom Coalition which advocates for regulations that protect consumers and curbs the sale of adulterated or synthetic products falsely marketed as kratom. For more information, visit globalkratomcoalition.org/kcac.
Media Contact
Dr. C. Michael White
[email protected]
###
SOURCE: Kratom Consumer Advisory Council (KCAC)
Copyright 2025 EZ Newswire
https://app.eznewswire.com/news/kratom-consumer-advisory-council-kcac-white-paper-debunks-7-product-safety-claims
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Ellis George LLP: CA Court of Appeal Upholds $5 Million Jury Verdict Against Bristol-Meyers-Squibb-owned Impact Biomedicines
Original verdict in Dr. James Brewer's fraud case reinstated by California Court of Appeal SAN DIEGO, July 21, 2025--(BUSINESS WIRE)--Ellis George LLP announced that The California Court of Appeal, Fourth Appellate District, has reversed a trial court order that reduced a jury verdict against Impact Biomedicines and instead reinstated the original $5,020,000 award. Impact Biomedicines, a division of Bristol-Meyers-Squibb, and Impact Biomedicine's founder and owner, Dr. John Hood, must pay San Diego physician and Alzheimer's researcher James Brewer M.D., Ph.D., more than $1 million in compensatory damages and $4 million in punitive damages in a fraudulent concealment case filed in 2019. Dr. Brewer, chair of the neurology department at UC San Diego, was represented by Christopher W. Arledge and Courtney L. Mitchell, both of Ellis George LLP, and Peter Afrasiabi of One LLP. At trial in the San Diego County Superior Court, a 12-member jury awarded Dr. Brewer more than $5 million, finding that Impact Biomedicines and Dr. Hood had defrauded Dr. Brewer as part of Impact Biomedicines' effort to end an FDA-mandated clinical hold and get Impact Biomedicines' experimental cancer drug approved. The jury accepted Dr. Brewer's argument that Impact Biomedicines and Dr. Hood had misled the FDA about the work Dr. Brewer had done for them and the conclusions he had reached and then concealed its false statements to the FDA from Dr. Brewer. Later, the trial court agreed that Dr. Brewer had proven his fraud case but reduced the damages number significantly. At the time, Mr. Arledge said he disagreed with the court's decision to reduce the damages and predicted that the trial court's order would be reversed on appeal. Today it was. According to the Court of Appeal's opinion, "We conclude that substantial evidence supports the jury's findings on liability and damages, and the jury's award of punitive damages was not constitutionally excessive…" "This was a hard-fought win against a very well-funded opponent and one of the largest, most-prestigious law firms in the country. Now a jury, a trial court, and an appellate court have all agreed that Dr. Brewer proved his fraud claim, and we're grateful to the Court of Appeal for recognizing that the trial court's reduction in Dr. Brewer's damages was a legal error," said Mr. Arledge. "This is an important win for Dr. Brewer and for patients who must be able to rely on the FDA drug-approval process." Impact Biomedicines was represented by Colleen C. Smith, John T. Ryan, Andrew R. Gray, and Melissa Arbus Sherry, all of Latham & Watkins. James Brewer v Impact Biomedicines, et al. Superior Court No. 37-2019-00067876-CU-CO-CTL About Ellis George LLP Ellis George LLP is an elite litigation and trial firm based in Los Angeles and with offices in San Francisco and New York. Whether plaintiff or defendant, individual, Fortune 500 corporation or entrepreneur, clients call upon Ellis George when seeking litigation counsel of the highest quality, creativity, dedication, and ethics. Visit View source version on Contacts Media Contact:Jim Goldman, GoldmanMediaGroup, for Ellis George LLPinfo@ 408-427-4349
Gizmodo
13 minutes ago
- Gizmodo
Garmin Is Going Nuts with the Vivoactive 5, Now at a New All-Time Low on Amazon for No Reason
Not everyone needs the new Garmin Fenix 8 at more than $1,000 to track its sporting progress. In fact, for 99% of us, the Garmin Vivoactive 5 is more than adequate. The watch is the perfect middle ground and delivers an excellent balance of performance, features and cost. No surprise, it's also a best-seller for those looking for a great fitness companion. Right now, you can purchase the Garmin Vivoactive 5 on Amazon for just $189, a staggering 37% off of its regular $299 price. This is the lowest price ever offered on this model, beating even past holiday discounts. If you're looking to upgrade or buy your very first fitness smartwatch, there's never been a better time to do so. See at Amazon The Vivoactive 5 brings together advanced health tracking and smart features in a lightweight and very elegant design. At the heart of the watch is its vibrant AMOLED display which delivers bright colors and sharp contrasts even under direct sunlight. With a battery life of up to 11 days in smartwatch mode, you'll spend less time charging and more time focused on training, recovery and day-to-day activities. What's more, the great Body Battery energy tracking offers you is a definite idea of how ready your body is by measuring the extent to which you are loaded or depleted. It takes into account your nap time, sleep quality, stress level and previous activity to customize information during your day. It's a powerful way to find out how your daily decisions are affecting your body and how to optimize your training or rest accordingly. If you want in-depth sleep tracking, the Vivoactive 5 includes advanced sleep analysis, and provides a sleep score and offering highly personalized sleep guidance. You'll get realistic, actionable guidance for improving your rest based on real facts, like your heart rate variability status. That is to say that your future health decisions are made with more than conjecture. Garmin creates watches that promote movement and the Vivoactive 5 is no different with over 30 integrated indoor and GPS sport apps. From running and cycling to HIIT, swimming, and even golf, there's a mode for all forms of movement. Wheelchair users were not left behind: a specific wheelchair mode monitors pushes rather than steps and includes special workouts and challenges. Automatic nap detection tracks naps and indicates how power naps influence your total energy, providing more information to assist in refining your routine. Health and wellness tracking extends far beyond the fundamentals as well. The Vivoactive 5 monitors your heart rate through your wrist, offers a daily morning report, estimates your fitness age and does menstrual and pregnancy tracking as well as stress tracking and meditation routines. If you're interested in pushing your fitness limits, the watch has high-end training features. The workout benefit feature tells you how each muscle-burning session will impact your body, and the recovery time guidance tells you how long you'll have to rest before you head out for your next session. You have the option to select preloaded workouts that vary from cardio, yoga, strength, HIIT, and Pilates, create your own using the Garmin Connect smartphone app. This deal is hard to pass up, so look for getting yours at this all-time low price. See at Amazon
Wall Street Journal
14 minutes ago
- Wall Street Journal
AstraZeneca Plans to Invest $50 Billion in U.S. by 2030
AstraZeneca AZN -0.60%decrease; red down pointing triangle said it plans to invest $50 billion in the U.S. by 2030, including a proposal for a new drug substance manufacturing center focused on weight-loss drugs. The U.K. biopharmaceutical giant said Monday the multi-billion dollar facility would produce drug substances for its weight-management and metabolic portfolio, including oral GLP-1s.
